WELCURE DRUGS & PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.74 INR | +3.72% |
|
-2.67% | +23.12% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 19.05 | 7.161 | 5.405 | 25.4 | 132 | 54.32 |
| Enterprise Value (EV) 1 | 18.93 | 7.011 | 5.352 | 24.93 | 131.4 | 54.31 |
| P/E ratio | -98.7 x | 184 x | -51.4 x | 41.3 x | 502 x | 53.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 38.1 x | 9.01 x | 6.55 x | 19.1 x | 126 x | - |
| EV / Revenue | 37.9 x | 8.82 x | 6.49 x | 18.7 x | 125 x | - |
| EV / EBITDA | - | - | - | - | - | 122,594,363 x |
| EV / FCF | -439 x | -7,011 x | -84.5 x | -249 x | 876 x | 159 x |
| FCF Yield | -0.23% | -0.01% | -1.18% | -0.4% | 0.11% | 0.63% |
| Price to Book | 96.2 x | 21.2 x | 34 x | 35.9 x | 142 x | 3.58 x |
| Nbr of stocks (in thousands) | 13,512 | 13,512 | 13,512 | 13,512 | 13,512 | 13,512 |
| Reference price 2 | 1.410 | 0.5300 | 0.4000 | 1.880 | 9.770 | 4.020 |
| Announcement Date | 6/18/18 | 8/24/19 | 5/22/20 | 5/26/21 | 5/26/22 | 7/11/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.5 | 0.795 | 0.825 | 1.333 | 1.05 | - |
| EBITDA | - | - | - | - | - | 0.443 |
| EBIT 1 | -0.205 | 0.024 | -0.097 | 0.046 | 0.2365 | 0.4108 |
| Operating Margin | -41% | 3.02% | -11.76% | 3.45% | 22.52% | - |
| Earnings before Tax (EBT) 1 | -0.193 | 0.039 | -0.0943 | - | 0.2358 | 1.017 |
| Net income 1 | -0.193 | 0.039 | -0.0943 | 0.551 | 0.2358 | 1.017 |
| Net margin | -38.6% | 4.91% | -11.43% | 41.34% | 22.46% | - |
| EPS 2 | -0.0143 | 0.002886 | -0.007782 | 0.0455 | 0.0195 | 0.0757 |
| Free Cash Flow 1 | -0.0431 | -0.001 | -0.0633 | -0.1002 | 0.15 | 0.3405 |
| FCF margin | -8.62% | -0.13% | -7.68% | -7.52% | 14.29% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | 76.86% |
| FCF Conversion (Net income) | - | - | - | - | 63.63% | 33.47% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/18/18 | 8/24/19 | 5/22/20 | 5/26/21 | 5/26/22 | 7/11/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 0.13 | 0.15 | 0.05 | 0.48 | 0.66 | 0.01 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -0.04 | -0 | -0.06 | -0.1 | 0.15 | 0.34 |
| ROE (net income / shareholders' equity) | -65.4% | 17.9% | -49.7% | 132% | 29% | 12.7% |
| ROA (Net income/ Total Assets) | -38.7% | 5.64% | -22.3% | 5.89% | 17.4% | 3.16% |
| Assets 1 | 0.4986 | 0.6916 | 0.4234 | 9.353 | 1.355 | 32.21 |
| Book Value Per Share 2 | 0.0100 | 0.0200 | 0.0100 | 0.0500 | 0.0700 | 1.120 |
| Cash Flow per Share 2 | 0.0100 | 0.0200 | 0 | 0.0400 | 0.0500 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 6/18/18 | 8/24/19 | 5/22/20 | 5/26/21 | 5/26/22 | 7/11/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +23.12% | 741K | |
| +15.21% | 69.5B | |
| -2.19% | 24.09B | |
| +8.13% | 8.2B | |
| -18.28% | 7.97B | |
| -0.98% | 7.84B | |
| +19.12% | 4.32B | |
| 0.00% | 4.19B | |
| -3.02% | 3.89B | |
| +23.97% | 3.62B |
- Stock Market
- Equities
- WELCURE6 Stock
- Financials Welcure Drugs & Pharmaceuticals Limited